{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:07:25Z","timestamp":1784660845640,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune checkpoint inhibitors has been reported to have synergic effects. This study aims to explore the safety and efficacy of long-course chemoradiotherapy combined with concurrent tislelizumab as a neoadjuvant treatment regimen for patients with locally advanced rectal cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This manuscript reported the interim result of a prospective, multicenter, single-arm, phase II trial. Patients with mid-to-low locally advanced rectal cancer with clinical stages of cT3-4a N0M0 or cT1-4a N1-2M0 were included. The patients received long-course radiotherapy (50 Gy\/25 f, 2 Gy\/f, 5 days\/week) and three 21-day cycles of capecitabine (1000 mg\/m2, bid, day1-14) plus concurrent three 21-day cycles of tislelizumab (200 mg, day8), followed by a radical surgery 6-8 weeks after radiotherapy. The primary endpoint was the pathological complete response rate. (Clinical trial number: NCT04911517)<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 26 patients completed the treatment protocol between April 2021 and June 2022. All patients completed chemoradiotherapy, 24 patients received three cycles of tislelizumab, and 2 patients received two cycles. The pathological complete remission (ypT0N0) was achieved in 50% (13\/26) of the patients with all proficient mismatch repair tumors. The immune-related adverse event occurred in 19.2% (5\/26) of patients. Patients with no CEA elevation or age less than 50 were more likely to benefit from this treatment regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Long-course chemoradiotherapy combined with concurrent tislelizumab in patients with locally advanced low rectal cancer had favorable safety and efficacy, and does not increase the complication rate of surgery. Further study is needed to confirm these results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1057947","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:02:15Z","timestamp":1675357335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiale","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiagang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800691019","article-title":"The mesorectum in rectal cancer surgery\u2013the clue to pelvic recurrence","volume":"69","author":"Heald","year":"1982","journal-title":"Br J Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7032","article-title":"Evolving treatment paradigm in the treatment of locally advanced rectal cancer","volume":"16","author":"Smith","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (Tme) versus preoperative chemoradiotherapy, tme, and optional adjuvant chemotherapy in locally advanced rectal cancer (Rapido): A randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01667","article-title":"Multicenter, Randomized, phase Iii trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (Stellar)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-Small-Cell lung cancer: A phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (Rationale-302): A randomized phase iii study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"Pd-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in mmr-proficient and mmr-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12957-022-02549-7","article-title":"Clinical benefits of pd-1\/Pd-L1 inhibitors in patients with metastatic colorectal cancer: A systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001444","article-title":"Current progress and future perspectives of neoadjuvant anti-Pd-1\/Pd-L1 therapy for colorectal cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: Initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase Ii, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunotherapy Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13014-020-01673-6","article-title":"Efficacy and safety-in analysis of short-course radiation followed by mfolfox-6 plus avelumab for locally advanced rectal adenocarcinoma","volume":"15","author":"Shamseddine","year":"2020","journal-title":"Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase Ii study of preoperative (Preop) chemoradiotherapy (Ctrt) plus avelumab (Ave) in patients (Pts) with locally advanced rectal cancer (Larc): The avana study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: A critical review on timing, dose and fractionation","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent pd-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage iii non-Small-Cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-022-09554-9","article-title":"Rationale and design of a prospective, multicenter, phase ii clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (Ncrt-Pd1-Larc trial)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.887525","article-title":"Efficacy and safety of Radiotherapy\/Chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41416-020-01071-5","article-title":"Beyond chemoradiotherapy: Improving treatment outcomes for patients with stage iii unresectable non-Small-Cell lung cancer through immuno-oncology and durvalumab (Imfinzi, astrazeneca uk limited)","volume":"123","author":"Patel","year":"2020","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cllc.2020.10.023","article-title":"Immune checkpoint inhibition with chemoradiotherapy in stage iii non-Small-Cell lung cancer: A systematic review and meta-analysis of safety results","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (Escort): A multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00290","article-title":"Randomized phase ii trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The checkmate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-Small-Cell lung cancer refractory to previous Pd(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.7176","article-title":"Wait-and-See Policy for Clinical Complete Responders after Chemoradiation for Rectal Cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.04.003","article-title":"Clinical complete response (Ccr) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. findings from the accord 12\/Prodige 2 randomized trial","volume":"115","author":"G\u00e9rard","year":"2015","journal-title":"Radiother Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.annonc.2021.05.054","article-title":"So-30 efficacy and safety of neoadjuvant short-course radiation followed by Mfolfox-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study","volume":"32","author":"Shamseddine","year":"2021","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3962-5","article-title":"The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer","volume":"22","author":"Lee","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22625","article-title":"Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer","volume":"109","author":"Das","year":"2007","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03056-6","article-title":"Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer","volume":"71","author":"Ugai","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1057947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:02:18Z","timestamp":1675357338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1057947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":37,"alternative-id":["10.3389\/fonc.2023.1057947"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1057947","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"1057947"}}